GlassScriptPhysician profile
Richard N Waldman
NPI 1851357313
$6,985.66
in general payments reported to CMS, 2019-2025
22 companies · $529 in 2025
The $529 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,938 · 2020: $534 · 2021: $457 · 2022: $608 · 2023: $1,503 · 2024: $1,418 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,274 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.93 |
| Education | $175.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,870.93 | 2019-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,025.75 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $604.93 | 2019-2024 | Otezla |
| Pfizer INC. | $552.01 | 2021-2025 | |
| Lilly USA, LLC | $532.59 | 2019-2024 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $379.64 | 2019-2024 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $364.52 | 2019-2020 | |
| Celgene Corporation | $358.57 | 2019 | |
| Genzyme Corporation | $315.29 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $250.00 | 2019 | |
| Ucb, INC. | $180.37 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $155.13 | 2024-2025 | Sotyktu, Camzyos |
| Incyte Corporation | $149.56 | 2022-2024 | Opzelura |
| Novo Nordisk INC | $91.65 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Shield Therapeutics INC | $24.13 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $22.00 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $21.01 | 2023 | Ycanth |
| Idorsia Pharmaceuticals US INC | $20.96 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $18.24 | 2025 | Farxiga |
| Galderma Laboratories, L.P. | $17.18 | 2021 | |
| Strata Skin Sciences, INC. | $16.84 | 2025 | Xtrac |
| Organon LLC | $14.36 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Waldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.